Business
Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors
Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"\n \n \n \n Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n April 8, 2021\n \n /CNW/ -\n \n Rakovina Therapeutics Inc. (the \"\n \n \n Company\n \n \n \")\n \n (TSXV: RKV) today announced that the Company has been granted patents entitled \"Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase\" by the European and Canadian Patent Offices.\n \n \n \n \n \n \n \n \n \n The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics' kt-2000 series, one of three novel series of DNA-damage response inhibitors being researched by the Company as potential targeted cancer therapies under a collaborative research agreement with the University of British Columbia.\n \n \n \"With our focus on the rapid progress of our research programs, we are pleased to receive these patent allowances in\n \n Europe\n \n and\n \n Canada\n \n ,\" said Prof.\n \n Mads Daugaard\n \n , Rakovina Therapeutics' president and chief scientific officer.  \"These patents further establish our strong global intellectual property protection and provide patent claims in\n \n Canada\n \n and the European Union into 2032, supporting our commitment to optimize drug candidates from the kt-2000 series for advancement toward the initiation of human clinical trials.\"\n \n \n \n \n About Rakovina's kt-2000 Series Drug Candidates\n \n \n \n \n Rakovina Therapeutics' kt-2000 series drug candidates are oral targeted small molecule inhibitors of poly (ADP-ribose) polymerase (PARP).  Established data demonstrate that lead candidates from Rakovina Therapeutics' kt-2000 series exhibit potency comparable to FDA-approved PARP-inhibitors and potent anti-cancer activity in preclinical animal models.  kt-2000 series lead candidates are being optimized around several differentiating factors and potential competitive advantages.\n \n \n \n \n About Rakovina Therapeutics Inc.\n \n \n \n \n Rakovina The...